IMMUNE CHECKPOINT INHIBITORS
Clinical trials for IMMUNE CHECKPOINT INHIBITORS explained in plain language.
Never miss a new study
Get alerted when new IMMUNE CHECKPOINT INHIBITORS trials appear
Sign up with your email to follow new studies for IMMUNE CHECKPOINT INHIBITORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New bladder cancer treatment combo tested in global trial
Disease control Recruiting nowThis study is testing whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder removal surgery helps control muscle-invasive bladder cancer better. The research involves 150 patients worldwide who are scheduled for bladder removal surgery…
Matched conditions: IMMUNE CHECKPOINT INHIBITORS
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
New drug combo aims to shrink tumors before stomach cancer surgery
Disease control Recruiting nowThis study is testing whether adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery is more effective for treating locally advanced stomach or gastroesophageal junction cancer. Researchers will compare the new combination to chemotherapy alone in…
Matched conditions: IMMUNE CHECKPOINT INHIBITORS
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Mar 06, 2026 15:38 UTC
-
Cancer patients share painful side effect stories
Knowledge-focused Recruiting nowThis study aims to understand the experiences of cancer patients who develop arthritis or muscle pain as side effects of immunotherapy. Researchers will interview 20 patients who developed these symptoms after cancer treatment. The goal is to learn how these side effects affect d…
Matched conditions: IMMUNE CHECKPOINT INHIBITORS
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:35 UTC